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Abstract
The relationship between periodontitis and systemic diseases is an important 
part of clinical periodontal research, which has been growing steadily. Even 
though the etiologies of periodontal disease and rheumatoid arthritis (RA) differ, 
these pathologies have many common features, both being multifactorial diseases 
characterized by localized chronic inflammatory reactions, which are fuelled by 
an analogous set of cytokines (among many, the most prominent being Tumour 
Necrosis Factor (TNF), Interleukin (IL) 6 and 17), leading to high systemic circu-
lating concentrations of inflammatory markers such as C-reactive protein (CRP). 
It was not until the discovery of peptidylarginine deiminase (PAD) mediated 
citrullination of proteins by Porphyromonas gingivalis that the link between the 
two diseases was purely speculative. This citrullination initiates a series of events 
which culminate in the production of anti-citrullinated protein antibodies (ACPA) 
and, finally, in the clinical manifestation of rheumatoid arthritis. Another com-
mon denominator is the bone destruction caused by proinflammatory cytokines 
secreted by T 17 helper cells (TH17) which is the pathological hallmark of both 
diseases. Other notable common areas are shared risk factors such as environmental 
and genetic risk factors. Regarding treatment, neither pathologies have a definitive 
cure, however, several strategies are employed, some of which are common, such 
as diet and lifestyle changes, and immunomodulating medication applied locally or 
systemically.
Keywords: periodontal disease, rheumatoid arthritis, cytokines, DMARDS, 
treatment, microorganisms
1. Introduction
The relationship between periodontitis and systemic disease is an important 
part of clinical periodontal research, which has been growing steadily since the late 
1980s. Monsarrat et al., in 2016 stated that approximately a third of all recent peri-
odontal studies address this issue [1]. Moreover, in the same year Loos published the 
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results of a study, accrediting the fact that a total of 57 different systemic diseases 
are being investigated for possible links [2].
This relationship is often described as "bidirectional", but the design of many 
epidemiological observational studies does not allow the relationship to be firmly 
established and, implicitly, any identified associations will be bidirectional until 
clarifying data appear. At present, there is no full understanding of the importance 
of the multiple associations reported and especially whether they play a causal role.
Although having different etiologies, periodontal disease (PD) and rheumatoid 
arthritis (RA) have many common features, both being multifactorial diseases 
characterized by localized chronic inflammatory reactions, which are fed by an 
analogous set of cytokines (Tumour Necrosis Factor (TNF)-α, Interleukins (IL) 6 
and 17), leading to high concentrations of inflammatory markers such as circulating 
C-reactive protein (CRP) [3]. In addition, bone destruction caused by proinflam-
matory cytokines secreted by helper T cells (TH17) is the pathological hallmark 
of both diseases. Furthermore, periodontitis and RA have certain risk factors in 
common such as environmental and genetic [4].
Rheumatoid arthritis is a chronic, autoimmune systemic inflammatory disease, 
characterized by an arthropathy with chronic, progressive, deforming and destruc-
tive evolution, having a major disabling character and multiple systemic manifesta-
tions that determine an important premature mortality. It affects 0.5-1.0% of the 
world's population, the cause however is still unclear [5]; having said all this, it is 
thought to be triggered by a combination of genetic and environmental factors that 
lead to the degradation of immune tolerance at the interface with mucosal surfaces, 
specifically in the lungs, intestines, and periodontium [6]. The effect is the trigger-
ing of the autoimmune response characterized by the production of rheumatoid 
factor (FR) and ACPA (anticitrullinated protein antibodies). Binding of ACPA to 
citrullinated epitopes in joints and the formation of immune complexes contain-
ing rheumatoid factor helps to form a vicious circle of tissue damage involving the 
activation of synovial macrophages and dendritic cells, and the release of proin-
flammatory cytokines and enzymes that lead to tissue degradation. At the same 
time, peptidilarginine deiminases (PAD) released by neutrophils during necrosis or 
during the production of extracellular traps citrullinate the proteins in the joints, 
resulting in a continuous local immune response that is self-sustaining [7].
Until a few years ago, despite these common features, it was difficult, if not 
impossible, to establish a potential causal link between the two diseases. The discov-
ery and characterization of an enzyme uniquely expressed by the major pathogen 
in periodontal disease Porphyromonas gingivalis, namely peptidilarginine deiminase 
(called PPAD to distinguish this bacterial enzyme from human peptidilarginine 
deiminase - PAD), was the basis for the hypothesis that protein citrullination medi-
ated by PPAD originating from inflamed periodontal sites may initiate a series of 
events that culminate in the production of anti-citrulline protein antibodies (ACPA) 
and ultimately in the clinical manifestation of RA [8].
The diagnosis of RA has been revolutionized by the discovery of ACPA, disease-
specific antibodies that are present in approximately 70% of patients with this 
pathology. These are strictly correlated with the severity of the disease and with 
major risk factors, genetic and environmental, suggesting a pathogenic involve-
ment. They are also detectable in the bloodstream 10 years before the onset of clini-
cal symptoms, suggesting that the initial loss of immune tolerance to citrullinate 
proteins is most likely a consequence of an inflammatory event that occurs outside 
the joint [9].
However, most proteins in the human body undergo certain post-translational 
changes, starting with proteolytic modifications, glycosylation processes or 
lipid changes, to modifications of residues by chemical or enzymatic means. 
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These changes represent, in fact, fundamental physiological processes necessary 
in order for the organism to function normally; however, by the generation of 
neo-epitopes, these changes can determine the formation of anti-modified protein 
antibodies (AMPA), for example ACPA, in subjects that are genetically susceptible 
and are subjected to certain risk factors [10].
As a chronic inflammatory disease, some of the characteristics and pathogenic 
processes of RA mirror those of periodontitis, both of which eventually result in the 
progressive destruction of bone. The profound interdependence between these two 
diseases is the result of common genetic and environmental risk factors, including 
HLA-DRB1 gene expression, smoking, and other exogenous risk factors such as 
nutrition, socioeconomic status, and psychological factors (stress). Despite the 
obvious differences in etiology, there is evidence linking the two diseases, clinically, 
epidemiologically, serologically and experimentally [11].
2.  Immunomodulatory medication in rheumatoid arthritis and its effect 
on periodontal disease
Given the similarities between the pathogenic aspects of periodontitis and rheu-
matoid arthritis, it is pertinent that the therapeutic options available for rheumatoid 
arthritis be known in the periodontal research community but also by periodontal 
specialists that have rheumatoid arthritis patients in treatment. Although the early 
mechanisms that result in impaired immune tolerance and the progression of 
clinical signs and symptoms of rheumatoid arthritis are unknown, the inflamma-
tory cascade plays a key role in all stages of rheumatoid arthritis pathogenesis, from 
autoimmunity to joint localization and joint destruction [12].
There are several treatment options available for patients with RA, imposed by 
international treatment guides that are independent of the oral and periodontal 
status, and these can include physical therapy, lifestyle changes such as diet and 
exercise in an effort to diminish joint stress, medication and even surgery. Among 
drugs the most common prescribed are non-steroidal anti-inflammatory drugs 
(NSAIDs) and so called anti-rheumatic disease-modifying drugs (DMARDs) [13].
The term DMARDs is used to name a group of drugs that are generally unre-
lated, but differ from NSAIDs (that have the purpose of reducing inflammation 
but not of treating RA) and also differ from steroids, that reduce the immune 
and inflammatory response but do not slow the progression of the disease. In 
other words, while NSAIDs and steroids are used to control RA symptoms, only 
DMARDS influences the progression of the disease [14].
DMARDS act as immunosuppressive and immunomodulatory agents and are 
divided in two major groups: conventional and biologic. Regarding the mechanism 
of action, each DMARD is unique and it is by consequence of the specific pathways 
it affects in the inflammatory cascade. In clinical practice the most frequently used 
conventional DMARDS are methotrexate, hydroxychloroquine, leflunomide, and 
sulfasalazine [13].
Biologics are the other major class of DMARDS made accessible for the first time 
in the early 90’s and are frequently prescribed when conventional therapy is not 
effective, objectified by clinical or radiological disease progression and on-going 
disease activity. This type of medication is highly specific and it targets a particular 
immune system pathway. Biological DMARDs include a number of anti-cytokine 
agents that block the activity of specific cytokines and are usually monoclonal 
antibodies that bind to the target cytokine [14]. Examples of biologics include TNF 
inhibitors (adalimumab, infliximab, certolizumab, etanercept), anti-CD20 (ritux-
imab), anti-CD80 and anti CD-86 (abatacept), anti-IL-6 (tocilizumab, sirukumab), 
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anti-IL-17 (secukinumab, ixekizumab) and Janus Kinase (JAK) inhibitors (tofaci-
tinib, baricitinib) to name a few [13].
DMARDs determine the reduction of the level of inflammatory markers such as 
CRP and rheumatoid factor (RF), the rate of erythrocyte sedimentation (ESR), and 
also cartilage and bone damage. In the treatment of rheumatoid arthritis, therapy 
with biological DMARDs is often prescribed in combination with a conventional 
agent in those patients that presented a limited response to conventional anti-
rheumatic disease-modifying therapy.
Tumor necrosis factor-alpha (TNF-α) is a particularly important proinflamma-
tory mediator and therefore, one of the primary objectives of the development of 
anti-cytokine therapies that have been introduced in the treatment of rheumatoid 
arthritis has been the development of anti-TNFα agents. Other cytokines that play 
a role in the pathogenesis of rheumatoid arthritis include interleukin-1 (IL-1), 
interleukin-6, interleukin-17, interleukin-15 and more recently interleukin-23 [14].
Additional studies are needed to better understand these mechanisms and help 
maintain general health, oral health parameters requiring close monitoring in RA 
patients.
Periodontal disease therapy by modulating the host response is a high inter-
est subject in periodontology and several classes of drugs have been proposed to 
fulfil this desiderate, some of them are even used in the treatment of rheumatoid 
arthritis. Amongst the potential host modulator drugs we mention NSAIDs, corti-
costeroids, conventional synthetic disease modifiers (DMARDs), matrix-metallo-
proteinase (MMP) inhibitors, clinically modified tetracyclines, anti-cytokines and 
biologic therapies, lipid mediators of resolution of inflammation, small molecule 
compounds, histone diacetylase inhibitors, RANKL inhibitors, bisphosphonates, 
Toll-like receptor inhibitors and also the combined anti-inflammatory and antibac-
terial approach [13].
Considering the common proinflammatory pathways between the two diseases, 
interactions with the immune system and the additional systemic inflammatory 
burden that accompanies periodontal disease we wanted to assess to what degree 
specific rheumatoid arthritis drug therapy influences periodontal status and if 
there is any difference regarding treatment combinations on oral status amongst RA 
subjects. Furthermore, we wanted to verify whether there is any difference in the 
severity of rheumatic disease and disease activity according to oral health status.
To accomplish this task we conducted a study on 220 patients with a verified 
diagnosis of rheumatoid arthritis in which we analysed the local inflammatory sta-
tus, by evaluating the Quigley Hein (QH) indices, the Lőe and Silness gingival index 
(GI), the papillary bleeding index (PBI), Probing Depth (PD) and the Community 
Periodontal Index of Treatment Needs (CPITN), accompanied by a detailed assess-
ment of the systemic status in patients with rheumatoid arthritis, including indexes 
of rheumatic disease activity but also systemic non-specific inflammatory markers 
such as C reactive protein (CRP) and erythrocyte sedimentation rate (ESR) [15].
There is no consensus in the literature regarding the severity of periodontal 
disease in rheumatoid arthritis patients, however authors agree that the percent-
age of moderate to severe periodontitis is higher in RA patients when compared to 
systemically healthy controls with periodontitis.
In our study, following the periodontal examination, 149 of the total 220 
patients with rheumatic pathology were diagnosed with moderate and severe peri-
odontitis, so from a percentage point of view we can say that 67.72% of the analysed 
group have moderate to severe periodontal damage. These results are similar with 
those from Erikson [16] who found a percentage of 75% out of 45 patients had mod-
erate or severe periodontitis, Rodríguez-Lozano [17] on the other hand, reported 
45% of 187 RA subjects had severe periodontitis and finally another study reported 
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an astounding 98% (out of 168 subjects) were suffering from moderate to severe 
periodontal disease [18].
Other than the oral status, from a systemic, rheumatic point of view we analysed 
the following disease markers:
2.1 Clinical status of rheumatic disease (Stage I to IV)
Stage 1: It is the incipient stage and involves the initial joint capsule inflam-
mation and synovial tissue swelling; causes evident symptoms of joint oedema, 
stiffness and pain.
Stage 2: Cartilage deterioration due to synovium inflammation which causes 
more important limitation of mobility.
Stage 3: Due to the substantial inflammation of the synovial tissue the bone 
is affected, not only the cartilaginous tissue. Subjectively, pain increases marked 
oedema, loss of muscle vigour and mobility, furthermore, deformations of the joint 
may appear.
Stage 4: In the ultimate stage of rheumatic disease the joints are no longer func-
tional and the inflammation stops. Subjects experience loss of mobility, stifness, 
oedema and pain.
On the studied cases, among the patients with rheumatoid arthritis, the distri-
bution of the subjects on the four stages was: stage I - 0.9%, stage II - 11.8%, stage 
III - 50.9% and stage IV - 36.4%.
2.2 VAS score (Visual Analogue Scale) for pain assessment
VAS (analogue visual scale) is a measuring instrument, often used in epide-
miological and clinical research to measure the intensity or frequency of various 
symptoms. Using a ruler, the score is determined by measuring the distance (mm) 
on the 10 cm line between the "pain-free" point and extreme pain, providing a range 
of scores between 0-100.
The VAS pain assessment score ranged from 10-90, with a mean value of 36.55 ± 
21.17, which included the study group with a moderate perception of pain.
2.3 DAS28
The DAS28 score (disease activity score) is a measure of disease activity in 
rheumatoid arthritis, 28 representing the examined joints. The range of measures 
of disease activity in RA is wide and it includes: assesement of joints for oedema 
and tumefaction, overall pain scores and general condition, inflammation serum 
biomarkers (eg ESR - erythrocyte sedimentation rate and CRP - C reactive pro-
tein), questionnaires, radiographic examinations, nuclear magnetic resonance and 
ultrasound.
DAS28 is a composite score, the results are entered into a complex mathematical 
formula to produce the overall score of disease activity. A DAS28 greater than 5.1 
involves active disease, less than 3.2 decreased disease activity, and less than 2.6 
remission.
2.4 Rheumatoid factor (RF)
For 86.4% of patients, rheumatoid factor was found to be positive. The cor-
relation of rheumatoid factor positivity with the staging of rheumatoid arthritis 
showed that 52.6% of patients with positive rheumatoid factor were in stage III of 
the disease, and 36.8% in stage IV (p = 0.014).
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2.5 AntiCCP antibodies (ACPA)
63.6% of patients had antiCCP antibodies. The correlation of the presence of 
antiCCP Ac with the staging of rheumatoid arthritis showed that 51.4% of patients 
with positive antiCCP Ac were in stage III of the disease, and 34.3% in stage IV  
(p = 0.451).
Among the associated comorbidities, on the studied cases, most frequently, the 
presence of hypertension (54.5%) and osteoporosis (31.8%) was noticed.
Regarding medication for RA, we observed that the most frequently prescribed 
were mainly the following: Leflunomide (46.4%) and Rituximab (44.5%), and 
Methotrexate 23.6%, of all cases, followed by 18.2% Adalimumab and 15.5% 
Tocilizumab. However, it is important to specify that the majority of patients 
have a combined medication of 2 drugs. The most frequent combination for our 
group are the following synthetic DMARDS combined with biological DMARDS: 
Methotrexate + Rituximab (11.8%) and Methotrexate + Adalimumab (6.4%) 
respectively. Another popular scheme was Leflunomide + Rituximab (20.9%), 
Leflunomide + Adalimumab (18.2%) and Leflunomide + Etanercept (11.8%).
When we analysed the correlation between ESR and medication, we observed 
that the lowest mean level is found in patients treated with Hydroxychloroquine 
+ Rituximab and Methotrexate + Adalimumab, and the highest was recorded in 
subjects who received Hydroxychloroquine + Tocilizumab.
Regarding the classic inflammatory marker (CRP), the lowest mean level was 
recorded in patients treated with Methotrexate + Adalimumab, and the highest in 
subjects treated with Hydroxychloroquine + Tocilizumab.
Measurement of periodontal indexes revealed the lowest mean Quigley Hein 
index was in subjects under a combination of Sulfasalazine and Rituximab therapy, 
and the highest scores were for Leflunomid and Etanercept combination.
GI index mean was lowest in subjects under Methotrexate or Leflunomide and 
Adalimumab combination, on the other hand, the highest was observed in the 
Leflunomide or Methotrexate and Rituximab combination. The lowest mean level 
of PBI is observed in patients treated with Leflunomid + Etanercept, and the high-
est in patients treated with Leflunomid + Rituximab. Regarding another specific 
clinical periodontal marker, the mean CPITN level did not differ significantly 
depending on the combined synthetic and biological DMARDS treatment.
In our study, RF was registered in a positive proportion of 86.4%, and the 
correlation of rheumatoid factor positivity with the staging of rheumatoid arthritis 
showed that as the joint damage is in a more advanced stage, so does the probability 
of the presence of RF.
In a systematic review in 2016, Fuggle et al. revealed that there is an increased 
risk of bleeding on probing (BOP) in patients with RA compared to subjects with-
out joint damage (p = 0.05), and in terms of oral hygiene parameters, the gingival 
index (GI) was significantly higher in level in RA compared to healthy controls; 
not the same was recorded in the plaque index analysis, another parameter of oral 
hygiene analysed in that study [19].
In 2015, Araújo et al. published a review of studies investigating the relationship 
between RA and periodontitis, in which articles were selected from 2012, including 
eight epidemiological studies, four periodontal intervention studies and five studies 
that investigated the role of inflammatory mediators in both diseases, highlight-
ing that 21 of studies confirmed the association of the two entities, by statistical 
analysis, while 3 studies demonstrated an association by descriptive analysis [20].
Two studies from 2013, Bıyıkoğlu et al., and Erciyas et al., respectively, 
analysed the effect of non-surgical periodontal therapy on the DAS 28 score, 
both observing a reduction of this parameter, with values that remained stable 
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post-treatment [21, 22]. Moreover, Erciyas et al. also analysed other parameters 
such as ESR and CRP and noted that the changes were more prominent in the 
group with high disease activity compared to the group with low activity [22].
In our study, the modified values of the analysed oral and periodontal health 
indices were significantly correlated with stage III or IV of RA. Most likely, the 
motor restrictions encountered by these patients make it difficult to achieve 
adequate oral hygiene; the burden of the disease in general affecting the quality of 
life can be additional factors in the subsistence of a poor periodontal status.
The analysed data in our study show that as the rheumatic damage increases, 
the oral status is altered in direct proportion to all indices, but especially in terms 
of GI and PBI which are relevant oral indicators in case of an exacerbated systemic 
inflammatory status, a fact confirmed by Payne in 2015 [23]. Our study thus 
represents an opening to the clinical correlation between periodontal inflammatory 
status and the degree of rheumatic damage.
Several studies have shown that non-surgical periodontal treatment is able to 
reduce serum levels of TNF-α, IL-1β, IL-6, IL-10, MMP-8 and C-reactive protein 
and to modulate RA activity in patients with moderate to severe periodontitis 
[24, 25].
Modulation of T cell activation has provided another therapeutic target in RA 
with the use of abatacept, and inhibition of alveolar bone loss has suggested that 
treatment with RA may also improve the progression of periodontitis [26]; how-
ever, this is only an experimental study, without clinical data on human subjects 
available just yet.
In conclusion, there is no definitive data in human subjects to evaluate the 
effects of DMARDs on periodontitis due to the small number of patients studied 
and the lack of randomized, double-blind, placebo-controlled studies. The use 
of anti-TNF antibodies did not consistently prevent alveolar bone loss and gener-
ated aggravated or improved gingival inflammation, depending on the specific 
drug used. It is not clear whether these divergent results reflect differences in the 
structure of the studied anti-TNF studies. To date, the most impressive beneficial 
effect has been observed in inhibiting IL-6 related to tocilizumab, an IL-6 receptor 
antibody. Subsequent studies with tocilizumab, as well as observations with anti-
IL-6 antibodies, may elucidate the importance of this cytokine in the pathogenesis 
of periodontitis.
The biological rationale for using DMARDS as a modulator of periodontitis 
expression in animals was confirmed by studies showing that mice deficient in the 
TN55-α p55 receptor developed less severe periodontal inflammation (reduced bone 
loss and a low inflammatory response) in response to inoculation with A. actinomy-
cetemcomitans [27]. Using the same model of experimental periodontitis induced by 
A. actinomycetemcomitans, researchers found that antigen-induced arthritis exacer-
bated alveolar bone loss, while anti-TNF-α therapies improved the development of 
periodontitis [28].
To date, most research on the use of anti-cytokine therapies for periodontitis 
in humans has been limited to small clinical trials evaluating periodontal status in 
patients with rheumatoid arthritis under treatment. The findings from these studies 
tended to be inconsistent and somewhat confusing, probably due to the small num-
ber of patients with a variety of periodontal conditions, selected due to the primary 
inclusion criterion (anti-cytokine therapy for rheumatoid arthritis), different from 
the recruitment situation which was a targeted and deliberate one, in accordance 
with their periodontal status.
A study of three groups of patients (one with autoimmune diseases including RA 
who were not treated with anti-TNF-α therapy, the second with RA who received 
anti-TNF-α therapy and the healthy control group without autoimmune disease, 
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and no anti-TNF-α treatment) identified that patients with autoimmune disease 
who did not receive anti-TNF-α treatment had severe levels of gingival inflamma-
tion, bleeding on probing, higher mean probing depths and higher concentrations 
of TNF-α in the crevicular fluid compared to subjects in the other two groups [29]. 
This research has shown that patients with autoimmune disorders (including RA) 
have a much more severe periodontal inflammation than patients who do not suffer 
from autoimmune diseases, anti-TNF-α therapy reducing inflammation in peri-
odontal tissues.
In our study, the combination of methotrexate and adalimumab had the low-
est ESR and CRP values, consistent with multiple studies attesting to the systemic 
anti-inflammatory effect of methotrexate in particular [30, 31]. The combinations 
of leflunomide and adalimumab, as well as leflunomide with etanercept, recorded 
the most marked decrease in both rheumatic disease and oral health indices, results 
similar to those of McInnes and Schett in 2017 which identified that patients with 
rheumatoid arthritis who received anti-TNF-α treatment showed statistically sig-
nificant improvements in probe depth, probe bleeding, and gingival inflammation 
compared to patients who did not receive anti-TNF-α therapy after non-surgical 
periodontal treatment [32].
The combination of leflunomide with rituximab or methotrexate with rituximab 
was associated in our study with the highest values of GI and PBI indices, data that 
coincides with similar studies in the literature [33]. Most likely these values are 
increased due to the inhibitory action of rituximab on CD20 B lymphocytes. When 
this drug binds to CD20 it triggers cellular death, which in time leads to almost 
complete depletion of peripheral B cells. Long-lived plasma cells that do not express 
this protein (CD20) are not directly affected by rituximab treatment, since this 
therapeutic agent only targets CD20 expressing cells.
Through our studies in which we analyzed the potential relation between the 
medication administered in rheumatoid arthritis and oral health indexes we could 
not confirm an effect on oral status of patients treated with conventional and 
synthetic DMARDS combination. An interesting finding is that patients treated 
with biologics had lower oral health indexes, thus a lower inflammation of the peri-
odontal tissues. We could observe the beneficial effect of TNF-α inhibitors which 
although administered systemically have a local effect [15].
Adequate oral health measures should be part of the routine recommendations 
offered to RA patients. Adequate periodontal diagnosis by a periodontal special-
ist is necessary to determine the optimum course of treatment. Reducing the oral 
inflammatory contribution to the total inflammatory load as a result of the favour-
able outcome of periodontal treatment is an important desideratum. Maintaining 
the complete health of patients with RA must be a collaborative effort. This part-
nership dentist - rheumatologist will certainly influence the oral and overall health 
of these patients.
There is a strong association between RA and periodontitis. Interventions to 
prevent, reduce or treat periodontitis in arthritis patients will certainly promote 
better health status for these patients.
3. Periodontopathogenic bacteria in rheumatoid arthritis patients
Several studies have shown that periodontitis is more common in patients with 
active RA compared to healthy people; also, the prevalence of RA is higher in people 
with periodontitis compared to subjects without periodontitis [34]. In addition, the 
course of periodontal disease in patients with RA was more severe, regardless of 
age, sex, ethnicity, or smoking history [5].
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Despite all the evidence supporting an association between these two diseases, 
the pathophysiological mechanisms have not yet been fully defined. In order to elu-
cidate the clinical, biochemical and immunological interrelationship, it is necessary 
to perform longitudinal, prospective, large multi-center clinical trials to eliminate 
the risk of bias given by medication or associated pathology, oral hygiene, socioeco-
nomic status, sex, age and vicious habits such as smoking.
Regarding the hypothesis of a causal link between periodontal disease and 
rheumatoid arthritis, where periodontitis is the determining factor, there are 
several theories in place.
The first one would be the release of extracellular traps by neutrophils (NET), in 
response to infection with P. gingivalis, structures characterized by active proteases 
and PAD. The concomitant action of these enzymes generates citrullinate epitopes 
and triggers the synthesis of ACPA. The production of citrullinate epitopes is 
accelerated by the synergistic action of gingipain and peptidilarginine deiminase 
of P. gingivalis (PPAD). Certain proteins from bacteria have the ability to mimic 
human proteins (bacteria enolase is similar to α-enolase in humans) on a molecular 
level and is thought to participate in the loss of immune tolerance to the organisms 
own molecules. Citrullinated epitopes in articular joints are the target of a second-
ary signal which causes increased generation of ACPA and rheumatoid factor, thus 
inducing immune complexes accumulation.
A second pathway would be neutrophil necrosis in the periodontal pocket, thus 
releasing danger-associated molecular patterns (DAMP) which circulate in the 
blood stream and exacerbate inflammation, both locally and systemically.
The third pathway is mediated by virulence factors expressed by P. gingivalis, 
such as lipopolysaccharides, fimbriae, gingipains, and lipoproteins, which are 
recognized by Toll-like receptors, protease-activated receptors, and/or NOD2 
receptors on gingival and phagocytic epithelial cells. In response to pathogens, 
host cells release cytokines and chemokines that activate the complement system, 
RANKL, and promote T-helper cell differentiation, thus contributing to osteoclas-
togenesis [11].
PPAD-dependent disorder of immune tolerance caused by P. gingivalis can 
be considered the causal link between periodontal infection and RA; However, 
endogenous PADs are also important because they have very high values in chronic 
infections, such as periodontitis [35].
Recent findings make it clear that these two pathologies are intimately connected 
not only by similarities in pathogenic mechanisms and genetic and environmental 
risk factors, but also by data provided by cohort studies showing that periodontitis 
precedes the development of RA and that periodontal disease in individuals who 
develop RA at a later date correlates positively with ACPA levels; all of these are 
important arguments that support a causal interrelationship.
In this disease model, the inflamed periodontal tissue is the site where immune 
tolerance to citrulline epitopes is surpassed and ACPA production begins, this 
theory being verified in animal studies and is consistent with the paradigm accord-
ing to which ACPAs are generated in mucosal surfaces, their formation preceding 
the clinical symptoms of rheumatic pathology for many years. In this case, peri-
odontal pathogens can be considered direct determinants of autoimmune reactions, 
this being supported by case-control studies showing the generation of ACPAs and 
other mucosal surfaces such as the lungs and gastrointestinal tract, illustrating a 
heterogeneous picture of bacterial-host interactions within the human microbiome 
complexity.
In order to clarify this issue we conducted a study [36] on 19 patients with 
rheumatoid arthritis in order to identify bacterial DNA, by PCR analysis, in the 
subgingival dental plaque and serum in patients affected by rheumatoid arthritis 
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and periodontitis. The patients were diagnosed with refractory severe rheumatoid 
arthritis, in spite of intensive DMARDs treatment which included methotrexate, 
sulfasalazine, leflunomide and chloroquine. Patients who had other comorbidities 
were excluded from the study, as well as pregnant or nursing women, antibiotic 
therapy or periodontal treatment in the last 3 months prior to the study.
All patients were treated with DMARDs most of them also benefited from 
NSAID medication and low-dose steroids. The diagnosis of periodontitis was 
determined by measuring the depth of the periodontal pocket (PD) and the clinical 
loss of attachment (CAL).
The disease time course of rheumatoid arthritis was 8.71 (± 5.99) years, with 
a range of 0.5-20 years from the initial clinical diagnosis of rheumatoid arthritis. 
Chronic periodontitis was the most common type detected, whereas the aggressive 
form was present in only 5% of analyzed subjects, although the sample size for this 
study was small.
When we investigated the stage of periodontal disease, the most commonly 
represented for our study group was the severe stage (42.2%), whereas moderate 
(36.8%) and mild (21.1%) were present to a lesser degree. These percentages are 
similar to other studies [17]. The average overall depth of the pocket was 3.9 mm, 
however, taking into account the biggest depth of the pocket of each dental unit, the 
average was 4.2 mm. In terms of loss of attachment, the upper molars were the most 
affected (3.85 mm average).
The periodontopathogenic load was considerable for this group of patients, as 
nearly 100% of the subgingival samples were positive for bacteria and the venous 
blood samples in 84.2%. In subgingival samples P. Intermedia (100%), T. denticola 
(84.2%) and P. gingivalis (78.9%) were the most frequently observed, and in venous 
blood P. Intermedia 73.6% and P. gingivalis 42.1%.
The least common species detected was A. actinomycetemcomitans (15.7%). 
When we compare the two types of samples we can observe no significant statisti-
cal differences regarding A. actinomycetemcomitans and P. gingivalis between the 
samples, other hand, other analyzed species did show statistically significant 
differences.
In this study, only 19 patients were included due to the difficulty of finding 
patients who met the inclusion criteria. Patients with refractory rheumatoid 
arthritis treated with DMARDs were selected because this condition was necessary 
to obtain a serum sample with significant detectable characteristics. Most patients 
were female (84.2%), and was consistent with the information that rheumatoid 
arthritis affects women more than men [4].
It is justified to argue that the lower concentration of bacteria DNA in the venous 
blood is due to the renal filtration. Other authors found similar data by using a 
checkerboard DNA-DNA-hybridization set up and bacterial DNA was detected in 
100% of analyzed serum samples thus implicating a continual aggression of oral 
pathogenic bacteria in joint disease [37].
In our study the most frequent bacterial species identified in venous blood 
were P. gingivalis, T. denticola and P. intermedia, the first two belonging to the red 
complex, and more often than not, correlated with a highly distructive periodontal 
disease pattern. On the other hand, A. actinomycetemcomitans which is thought to 
be mainly responsible for a more rapidly progressive type periodontitis, was less 
frequently detected. The reason could be that only one patient was affected. These 
data are consistent with previous reports.
The fact that A. actinomycetemcomitans and P. gingivalis did not show statistically 
significant differences between samples suggests that this could be a significant 
bacterial association for rheumatoid arthritis patients because the same bacteria 
species detected in serum were present also in bacterial plaque samples. On the 
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other hand, there were statistical differences between samples for P. intermedia, 
T. forsythia, P. nigrescens and T. denticola, suggesting a more minor role for these 
periodontal pathogens.
The tooth associated microflora has been extensively studied. The presence of 
Porphyromonas gingivalis, Tannerella forsythia, Aggregatibacter actinomycetemcomitans 
in the gingival sulcus poses an increased risk for developement and severity of 
periodontitis. Healthy versus diseased periodontal sites are different in terms of 
microbiological composition. The healthy sulcus has a lower bacterial load and also 
less morphological types, whereas the periodontal pocket is a complex microenvi-
ronment with an abundance of microorganisms that are mostly anaerobic gram-
negative periodontopathogens [38].
Another interesting result of our study is the fact that all bacterial serum 
positive patients were also positive for the same bacteria in the subgingival plaque, 
thus proving a direct link to the oral cavity. On a similar note, some studies in the 
literature discovered antibodies against P. intermedia in periodontal tissues and in 
the synovium of subjects with rheumatoid arthritis. Moreover, the induction of 
proinflammatory cytokines in the synovial tissue of rheumatoid arthritis subjects is 
exacerbated by elevated heat shock protein 70 expressions precipitated by specific 
stress stimulating factors [39]. This confirms our results which place P. intermedia as 
the most frequently identified bacteria in rheumatoid arthritis subjects.
Whole-genome shotgun (WGS) sequencing is a newer technique that analyzes 
bacteria genomes with important roles in a metagenomic sample. Through this 
method a more global, complex image of the microbial ecosystem is obtained 
because it examines the metabolic pathways and the complete set of genes pertain-
ing to the community.
A recent study determined that species of Prevotella (microorganisms of oral 
origin) are increased in the gut microbiome of rheumatoid arthritis subjects [40]. 
These results are sustained by another study performed on patients in preclinical 
rheumatoid arthritis stages that reported high numbers of Prevotella spp in these 
patients [41]. Thus colonization by oral microorganisms of the gut could be linked 
to the pathogenesis of rheumatic diseases.
Metagenomic studies are an important research direction that could establish 
other links in the periodontitis-rheumatoid arthritis binome, and have the potential 
to better determine the microbial diversity and ecology in these subjects.
Considering the presented data it is fair to articulate an important role of oral 
pathogens DNA in the pathogenesis of rheumatic diseases. The migration of DNA 
from periodontal pockets to the joints could be by means of the free bacterial DNA. 
This information can be valuable for future studies to elucidate whether periodontal 
pathogenic DNA might be a possible trigger for rheumatoid arthritis development.
4.  Future research possibilities in the rheumatoid arthritis-periodontitis 
interface
Host response modulation therapy is a highly researched topic in the scientific 
literature, and more specifically, when referring to the management of periodontal 
disease, a number of potential drugs have been considered for treatment. The first 
studies on this topic date back 30 years ago and they analyzed the intake of nonste-
roidal anti-inflammatory drugs for the minimization of alveolar bone loss. Due to 
the fact that they were prescribed for long periods of time, important undesirable 
side effects were associated with their administration, and thus precluding their 
use as adjunctive therapy for periodontitis; in other words, the associated risks far 
outweigh any potential benefits in reducing alveolar bone resorption.
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In the 1990s, a new wave of research investigated the use of tetracycline com-
pounds, specifically doxycycline, after identifying its efficacy as an inhibitor of 
matrix metalloproteinases. Randomized controlled clinical trials have confirmed 
a benefit of using subantimicrobial doses (20 mg twice daily for 3 months) as an 
adjunct to conventional non-surgical treatment, with no evidence of undesirable 
side effects. To date, this dose of doxycycline is the only drug therapy widely avail-
able, authorized as a host modulating agent for use in the treatment of periodontal 
disease. However, not all studies have shown the same clear benefit as seen in large-
scale clinical trials, and there are still uncertainties about the category of patients 
for whom such treatment would provide feasible results, and can be anticipated in 
routine periodontal practice [42].
Anti-cytokine therapies have a proven efficacy in the management of rheuma-
toid arthritis and, given the similarities between the pathogenesis of rheumatoid 
arthritis and periodontitis, researchers' interest in anti-cytokine therapies as 
potential modulators of the host response in the treatment of periodontitis is justi-
fied. However, there are concerns associated with their use due to well-documented 
side effects, such as an increased risk of infection and malignancy [43]. In addition, 
cytokines function in complex cellular and molecular networks that integrate 
aspects of innate and adaptive immunity that are still challenging to assess in their 
complexity.
Similar to other autoimmune and chronic inflammatory conditions, our 
knowledge of all cytokine functions in periodontitis is far from exhaustive, and 
simple inhibition of a certain cytokine may not determine a clinically significant 
impact on the researched pathological condition. This is due to the fact that a great 
deal of cytokines and biomolecules exert a similar effect on the cells they interact 
with, thus it is possible that inhibition of a certain cytokine could have little to no 
detectable influence on a pathological condition. This is by consequence of other 
cytokines which have a similar function to the one that was repressed. In addition, 
even though animal models may suggest certain anti-cytokine drugs that could 
ameliorate, or even amend, the course of a disease such as rheumatoid arthritis, 
they cannot predict exactly whether the same efficacy can be obtained in human or 
individual patient studies.
In the treatment of rheumatoid arthritis, inhibition of TNF-α with antagonist 
therapies plus methotrexate has clearly demonstrated clinical improvements, due to 
the fact that this molecule is of major importance in the pathogenesis of the disease. 
Moreover, anti-TNF-α therapy in patients with rheumatoid arthritis results in a 
reduction of other pro-inflammatory mediators, such as IL-1β and IL-6, leading 
to an improvement of the anti-inflammatory effect [32]. Even so, the use of these 
therapies does not lead to complete eradication of the disease, and success factors 
are assessed using composite scales that take into account not only the improvement 
quantified in percentage in the clinical signs and symptoms of the disease, but also 
the high cost and high risk of significant side effects.
The method of administration (typically repeated subcutaneous injections or 
intravenous infusions) is another limiting factor; however, it is possible that future 
generations of anti-TNF-α agents (possibly even locally released) may have a much 
higher impact on the treatment of periodontitis.
Compounds with small molecules, for example histone deacetylase inhibitors, 
could potentially successfully manage certain pathological conditions that deter-
mine bone resorption. Considering the fact that they have an inhibitory effect on 
the activity of osteoclasts they could be coupled with anti-inflammatory drugs for 
the minimization of inflammation and osseous resorption. Another area of interest 
is the advancement of synthetically produced specific deacetylase inhibitors target-
ing the histone diacetylases that are implicated in the dysfunction process [44].
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On the other hand, the potential side-effects on other cellular processes are not 
to be ignored and supplementary studies characterizing the risk-benefit ratio are 
paramount. Another potentially confounding or even aggravating factor may be the 
difference in mechanism of action of biological therapies in animal versus human 
subjects which could have unfortunate consequences when applied for the first 
time. In spite of all this, these compounds are currently being evaluated in early-
stage clinical trials as a treatment plan in neoplasms and show promising prelimi-
nary results in terms of effectiveness and toleration [45].
A newly emerging class of drugs that shows great promise in the adjunctive 
treatment of periodontal disease is pro-resolution lipid mediators. A major benefit of 
these endogenous compounds is that they are generated as a physiological response 
to inflammation (resolution agonists), contrary to inhibitors of inflammation that 
may imperil host defense [46]. The development of drugs that mimic the actions of 
endogenous mediators that lead to the resolution of inflammation could be useful in 
the treatment of a number of chronic inflammatory diseases, including periodontitis; 
obviously, efforts to demonstrate their safety and effectiveness will be commensurate.
Therefore, the immunomodulatory properties of a number of molecules and 
classes of drugs are being investigated, with the precise purpose of evaluating the 
applicability in the treatment of periodontal disease. The challenge at hand that still 
remains is to capitalize on the information gained from fundamental studies and 
animal model experiments in order to promote the development and evaluation 
of these compounds as novel therapeutic options. Furthermore, assessment of the 
risk/benefit ratio driven by large scale clinical use, taking into account the potential 
diversity in the response profile in-between subjects, interactions with other medi-
cation and potential adverse effects is imperative. Nonetheless, it is highly possible 
that in the future a new series of modular anti-inflammatory and pro-resolving 
therapies will be identified; these therapeutic agents could have direct relevance as 
adjuvants in the treatment of periodontal disease.
5. Conclusions
Significant evidence suggests that citrullination may bind periodontal disease 
to rheumatoid arthritis. Genetic factors drive host responses to chronic diseases 
with complex pathogenesis. In the future, more effective therapeutic approaches 
will include multiple synergistic therapies to modulate the host response, combined 
with treatments that target microbial etiology. Further studies are needed to better 
understand these mechanisms and help maintain overall health, with oral health 
parameters requiring close monitoring in patients with RA.
Given the similarities between aspects of the pathogenesis of periodontitis and 
rheumatoid arthritis, it is relevant that in the periodontology research community 
there is a great deal of interest for optimizing the treatment options applicable in 
rheumatoid arthritis patients. Even though impaired immune tolerance and intro-
duction of symptoms in rheumatoid arthritis have yet to be fully comprehended, it 
is evident that concerning the pathogenesis of this disease the inflammatory cascade 
is the leading actor from start to finish; beginning with the initiation of autoimmu-
nity, to the subsequent synovial localization, and culminating in the joint and bone 
tissue destruction.
Interventions to improve oral pathology can have direct and indirect systemic 
benefits. Considerations which must be taken into account include the patient's abil-
ity to maintain adequate oral hygiene, xerostomia and associated complications due 
to drug intake or disease course, the patient's susceptibility to infections, alterations 
in hemostasis, and drug mechanism of action and interactions.
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